The Peptide NewsroomPeptide research, industry and supply-chain headlines

Second Texas Pharmacy Recalls Injectable Glutathione as FDA Flags Endotoxin Risk

Chemical structure diagram of glutathione
Structure rendering: PubChem, National Library of Medicine (public domain)

A Houston compounding pharmacy is recalling one lot of injectable glutathione after testing found elevated levels of bacterial endotoxins, according to a report on the FDA notice. It is the second Texas pharmacy to issue a recall of injectable products over endotoxin concerns, weeks after an Austin compounding pharmacy announced a similar action.

The product is compounded glutathione 200 mg/mL in 30 mL multi-dose vials, distributed by Optimal Balance Pharmacy. Glutathione is a naturally occurring antioxidant made by the liver, and the compounded injectable versions of it are used off-label by the wellness and cosmetics industry.

Why endotoxins matter

The FDA said injectable products with elevated bacterial endotoxin levels could cause serious and potentially life-threatening reactions, listing fever, low blood pressure, inflammatory reactions, anaphylactic shock and death among the possible outcomes. That is not a theoretical hazard in an injectable: it is the reason sterile compounding is held to the standard it is.

The elevated levels turned up in the pharmacy's own testing, which is what triggered the action. The recall covers a single lot, not the pharmacy's full product range.

Reports already in hand

Optimal Balance Pharmacy has received reports of adverse events, according to the FDA. Those reports included fever, chills, severe headache, nausea, vomiting, pain, and symptoms consistent with an allergic reaction.

Fourteen states

The recalled lot went to consumers in 14 states: Texas, Arizona, Colorado, Florida, Illinois, Louisiana, Michigan, New York, Nevada, Oklahoma, Pennsylvania, Utah, Vermont and Washington. It carries product code LG342009076 and a use-by date of October 4, 2026, and was supplied as a multi-dose vial.

A product the agency never assessed

The FDA has not reviewed or approved any version of injectable glutathione for safety and effectiveness, and the benefits of injectable glutathione are described in the report as not well-defined. That gap has not slowed the market: the injections are widely used off-label for skin brightening and reduction of hyperpigmentation, as well as for cellular detoxification, immune support and countering oxidative stress.

What holders of the lot are told

Anyone holding products from the affected lot should stop using them immediately and quarantine them, according to the pharmacy, then contact Optimal Balance Pharmacy to arrange retrieval and proper disposal. Anyone experiencing symptoms that may be related to the recalled product should contact a physician immediately, the pharmacy said.

Bottom line

Two Texas compounders in a matter of weeks, same failure mode, same route of administration. The report does not state how many vials were distributed or whether further lots are under review, and those are the two numbers worth watching.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: safety, fda

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

GLP-1 Drugs Linked to Rare Sudden Vision Loss, But Absolute Risk Stays Low

A Rutgers-led study published in Annals of Internal Medicine links GLP-1 drugs including Ozempic and Wegovy to a modest increase in ischemic optic neuropathy, a rare condition that can cause sudden vision loss. The lead author put the increase at roughly three to four additional cases per 10,000 patients over 18 months, and says the data does not establish causation.

Telangana Regulator Warns Online Peptide Buyers Risk Contamination, Serious Reactions and Death

Telangana's drug regulator TG SAFE has warned against buying or self-administering unapproved weight-loss drugs and experimental peptides sold on Telegram and other online platforms, naming BPC-157, GHK-Cu, retatrutide and tesamorelin. The advisory says such products may be contaminated, mislabelled or untested for sterility, and directs doctors not to prescribe them.

Gray Market Peptide Users Report Months of Side Effects, and the Research Is Thin

KFF Health News, written up by Futurism, reports on users of research-grade BPC-157 who describe fatigue, spasms and migraines lasting months after a few days of use. A former FDA official quoted in the piece says robust human studies on these compounds remain rare.